Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj

Japanese Encephalitis Clinical Trial

— BR-JELITE  

Official title:

A Multi-center, Open, phase4 Study to Assess the Long-term Immunogenicity and Safety of Fourth Administration of BR JEV and to Investigate on Vaccine Interchangeability in Children Aged 6 Years Who Received 3 Doses With ENCEVAC or JEV-GCC

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02532569
• Other study ID #: BR-KD-287-CT-401
• Status: Completed
• Phase: Phase 4
• First received: August 21, 2015
• Last updated: February 3, 2017
• Start date: August 2015
• Est. completion date: October 2016

Study information

• Verified date: February 2017
• Source: Boryung Pharmaceutical Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A multi-center, open, phase 4 clinical trial to assess the long-term immunogenicity and safety of fourth administration of Boryung Cell-Culture Japanese Encephalitis Vaccine inj. and to conduct an exploratory investigation on vaccine interchangeability in Korean children aged 6 years who received primary 3 doses with ENCEVAC® or Japanese Encephalitis Vaccine-GCC® inj.

Description:

This is a follow-up study of KD287-BR-CT-301 (ClinicalTrials.gov identifier: NCT01150942), a phase 3 study to investigate the efficacy and safety of a cell-culture Japanese encephalitis vaccine (ENCEVAC®) compared with that of a mouse brain-derived Japanese encephalitis vaccine (Japanese Encephalitis vaccine-GCC® inj). Subjects participated in KD287-BR-CT-301 study were to receive 3 doses of Japanese encephalitis vaccine (JEV) assigned by randomization from the age of 12 months and those subjects who completed the 3 doses of JEV are the target population in this study. The purpose of this study is to investigate the long-term immunogenicity and safety of the booster (fourth) dose of JEV, which will be given as Boryung Cell-Culture Japanese Encephalitis Vaccine inj, proven to be same with ENCEVAC® but manufactured by a different manufacturer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 94
• Est. completion date: October 2016
• Est. primary completion date: October 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years to 7 Years

Eligibility

Inclusion Criteria:

• Parent/guardian (legally authorized representative) has given voluntary written consent to the subject's participation after being fully informed of the purpose, methods, risks, and benefits of the study.

• Male and female children who have completed the primary 3 doses of JEV in the KD287-BR-CT-301study.

• Male and female children reaching at least 6 years of age on the day of booster dosing of JEV.

• Male and female children who are identified to be healthy based on physical examination and medical history.

Exclusion Criteria:

• Children who have acute febrile illness with tympanic temperature of =38.0 ? on the day of booster dosing of JEV.

• Children who have moderate or severe acute disease (regardless of fever).

• Children who have history of encephalitis, encephalopathy, cerebromeningitis, or convulsion.

• Children who have received JEV (including live JEV) other than the investigational products administered in the KD287-BR-CT-301study.

• Children who have had fever (= 40 °C) or systemic allergy within 48 hours after vaccination.

• Children who have shown anaphylactic reaction to the investigational products administered in the KD287-BR-CT-301study or who are likely to be allergic to the ingredients of the investigational product.

• Children who have been diagnosed with immunodeficiency such as acquired immune deficiency or who have family history of immunodeficiency.

• Children who have received other vaccines within 28 days before booster dosing of JEV (vaccines to be administered according to the national vaccination program.

• Children who have received immunosuppressive thera-py within 28 days before booster dosing of JEV.

• There is a possibility that immune globulin preparations has not been excreted enough on the day of booster dosing of JEV if children have received such a product.

• Children who are currently participating or planning to participate in other clinical stud-ies during the study period.

• Other ineligible conditions judged at the discretion of principal investigators or subinvestigators.

Related Conditions & MeSH terms

• Encephalitis
• Encephalitis, Japanese
• Japanese Encephalitis

Intervention

Biological:
• Japanese encephalitis vaccine
Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.

Locations

Country	Name	City	State
Korea, Republic of	Inje University Ilsan Paik Hospital	Goyang	GyeongGi-Do
Korea, Republic of	Gachon University Gil Medical Center	Incheon
Korea, Republic of	Inha University Hospital	Incheon
Korea, Republic of	Ewha Womans University Mokdong Hospital	Seoul
Korea, Republic of	Korea Cancer Center Hospital	Seoul
Korea, Republic of	KyungHee University Hospital	Seoul
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Wonju Sevrance Christian Hospital	Wonju	Gangwon-do

Sponsors (1)

Lead Sponsor	Collaborator
Boryung Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the seroconversion rates before and after the fourth dose of JEV		Day 28 (28 days after booster dose)]
Secondary	To assess the seropositive rates before and after the fourth dose of JEV		Day 28 (28 days after booster dose)]
Secondary	To assess the geometric mean titer (GMT) before and after the fourth dose of JEV		Day 28 (28 days after booster dose)]
Secondary	To assess the percentage of subjects who develop neutralizing antibody titers		Day 28 (28 days after booster dose)
Secondary	To assess the percentage of subjects in their neutralizing anti-body titers		Day 28 (28 days after booster dose)